Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCShugeng Gao, Jie He, Xiuli Tao et al.|Journal of Thoracic Oncology|2020Cited by 415
Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic surveyJufang Shi, Min Dai, Le Wang et al.|Lung Cancer|2018Cited by 134
Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analysesW J Guo, Shugeng Gao, Liang Zhao et al.|European Journal of Cancer|2025Cited by 2